14.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
What analysts say about Arcutis Biotherapeutics Inc. stockOver 200% growth - PrintWeekIndia
Goldman Sachs Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Neutral Recommendation - MSN
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Goldman Sachs Initiates Coverage On Arcutis Biotherapeutics (ARQ - GuruFocus
Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs - TipRanks
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - The Manila Times
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Using Too Much Debt? - 富途牛牛
Is Arcutis Biotherapeutics Inc. a good long term investmentDynamic growth stocks - jammulinksnews.com
Arcutis Biotherapeutics Inc. Stock Analysis and ForecastExponential return rates - jammulinksnews.com
What drives Arcutis Biotherapeutics Inc. stock priceAccelerated wealth building - jammulinksnews.com
Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth - Investing.com India
(ARQT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st
Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada
Arcutis Biotherapeutics Earns Relative Strength Rating Upgrade; Hits Key Benchmark - MSN
Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN
FDA News and Decisions: Midyear Updates - Dermatology Times
Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN
(ARQT) Investment Analysis - news.stocktradersdaily.com
Arcutis Biotherapeutics - WBFF
Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria
Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan
Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus
ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis - Stock Titan
Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):